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Abstract: Aberrant hyperactivation of nuclear factor erythroid 2 (NF-E2) p45-related factor 2 (NRF2)
is a common event in many tumour types and associates with resistance to therapy and poor patient
prognosis; however, its relevance in colorectal tumours is not well-established. Measuring the
expression of surrogate genes for NRF2 activity in silico, in combination with validation in patients’
samples, we show that the NRF2 pathway is upregulated in colorectal tumours and that high levels of
nuclear NRF2 correlate with a poor patient prognosis. These results highlight the need to overcome
the protection provided by NRF2 and present an opportunity to selectively kill cancer cells with
hyperactive NRF2. Exploiting the CRISPR/Cas9 technology, we generated colorectal cancer cell lines
with hyperactive NRF2 and used them to perform a drug screen. We identified AT9283, an Aurora
kinase inhibitor, for its selectivity towards killing cancer cells with hyperactive NRF2 as a consequence
to either genetic or pharmacological activation. Our results show that hyperactivation of NRF2 in
colorectal cancer cells might present a vulnerability that could potentially be therapeutically exploited
by using the Aurora kinase inhibitor AT9283.
Keywords: NRF2; colorectal cancer; drug screening
1. Introduction
The transcription factor NRF2 (nuclear factor erythroid 2 (NF-E2) p45-related factor 2, encoded by
NFE2L2) is the master regulator of oxidative stress responses, which allows adaptation and survival
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during stress conditions. In normal cells under nonstress conditions, NRF2 levels and activity are kept
low by its fast proteasomal degradation, which is principally facilitated by KEAP1 (a substrate adaptor
for a Cul3-based E3 ubiquitin ligase) [1,2]. Although NRF2 is a well-characterised cytoprotective
factor in normal cells, its sustained activation protects tumour cells against chemo- and radiation
therapies and promotes metabolic switches that support cell proliferation and tumour growth [3–7].
Sustained activation of the NRF2 pathway is mainly due to either loss-of-function (LOF) mutations in
KEAP1 [3,8] or gain-of-function (GOF) mutations in NFE2L2 [8,9]. This has been shown in a variety of
tumours [3,8]. Somatic mutations of NRF2/KEAP1 are particularly prevalent in lung adenocarcinoma
(LuAD) and squamous cell carcinoma (LuSCC) [8,10–12]. It is estimated that 34% LuSCC and 18%
of LuAD patients harbour mutations in NRF2 or KEAP1, which correlates with poor survival [11,13].
Additionally, aberrant activation of NRF2 in cancer cells also occurs through alternative mechanisms,
including the oncogene-induced transcription of NRF2 via KRAS, BRAF, MYC activation [14,15] or
epigenetic silencing of KEAP1 [16,17].
Altogether, this shows that the aberrant activation of the NRF2 pathway might be a common
pro-oncogenic event in many cancer types, and thus, the identification of ways to overcome the
protection provided by NRF2 is a desirable goal. Despite efforts to identify selective NRF2 inhibitors,
chemical inhibitors of NRF2 identified to date lack potency and/or specificity, and none have entered
clinical trials [18–23]. Furthermore, the safety of a systemic treatment with an NRF2 inhibitor for
patients is uncertain due to the critical cytoprotective role of NRF2 in normal cells and its important role
in the immune response [24–26]. An alternative way to overcome the NRF2-mediated aggressiveness
in cancer is to identify vulnerabilities associated with NRF2 hyperactivation. Since such an approach
is not expected to affect normal cells, it will be more specific and, consequently, safer than systemic
NRF2 inhibition.
In colorectal cancer, genetic alterations of KEAP1 or NFE2L2 are rare (less than 2%). The activation
of NRF2 in colorectal cancer has been shown to happen through at least two different mechanisms:
hypermethylation of the KEAP1 promoter and deubiquitination of NRF2 [16,27]. However, the actual
contribution of NRF2 to tumour development and therapeutic responses in colorectal cancer remains
unclear, with conflicting data regarding NRF2 levels, the relevance of its localisation and correlation
with prognosis [28–34]. Further, the use of potentially unspecific NRF2 antibodies [35] and the lack
of antibody validation for in immunohistochemistry analyses call the results of some studies into
question. This is in contrast with lung cancer, where, in addition to the existence of well-characterised
cell lines harbouring mutant hyperactive NRF2 (e.g., the lung cancer cell line A549), several models
have been developed to study NRF2 hyperactivation, and a number of associated vulnerabilities have
been identified by using KEAP1-deficient or loss-of-function mutant models [36–39]. In addition to
NRF2, KEAP1 also interacts with other proteins [40], but the number of studies addressing the role of
NRF2 hyperactivation in the presence of wild-type KEAP1 is limited.
To fill these gaps, in this study, we first investigated the activation of the NRF2 pathway and its
correlation with prognosis in colorectal tumours by performing a comprehensive in silico analysis.
The activation of NRF2 in colorectal tumours compared to matched normal tissue was then validated
in samples from patients. Furthermore, we generated isogenic colorectal DLD1 cell lines harbouring
gain-of-function (GOF) mutations in NRF2. Using this model, we screened a panel of 528 drugs for
their ability to kill DLD1 cells with hyperactive NRF2 whilst sparing DLD1 cells expressing “normal”
levels of NRF2. Remarkably, we found that DLD1 NRF2-GOF cells are more sensitive to a number
of Aurora kinase inhibitors compared to DLD1 control cells. Furthermore, we validated the best
hit from the drug screening, the Aurora kinase inhibitor AT9283, and showed that the genetic and
pharmacological activation of NRF2 increases the drug sensitivity to AT9283.
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2. Materials and Methods
2.1. Cell Culture
All DLD1 cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing
10% Fetal Bovine Serum (FBS) at 37 ◦C and 5% CO2. The cell lines were validated by Short Tandem
Repeat (STR) profiling and were routinely tested to ensure that they were mycoplasma-negative.
CRISPR-edited NRF2 knockout (NRF2-KO) and NRF2 gain-of-function (NRF2-GOF) DLD1 cell lines
were produced as previously described [41].
2.2. Antibodies and Reagents
Antibody recognising NRF2 (D1Z9C) for Western blotting analyses was obtained from
Cell Signaling Technology (Danvers, MA, USA) and for immunohistochemistry (IHC) from
Santa Cruz Biotechnology (sc-365949) (Dallas, TX, USA). Anti-beta-actin antibody (C4) was
from Santa Cruz Biotechnology. Horseradish peroxidase (HRP)-conjugated secondary antibodies
were from Life Technologies (Carlsbad, CA, USA). AT9283 was purchased from ApexBio
Technology (Houston, TX, USA). Dimethyl sulfoxide (DMSO) was from Sigma-Aldrich (Dorset, UK).
R,S-sulforaphane (SFN) was purchased from LKT Laboratories (St. Paul, MN, USA). The (±)-TBE-31
and HB229 were kindly provided by Honda and Wells, respectively [42,43].
2.3. Quantitative Real-Time PCR (rt-qPCR)
The use of human tissues was approved by the Tayside Tissue Bank Research Ethics Committee,
a devolved subcommittee of the Tayside Committee on Medical Research Ethics.
RNA from tissue or cells was extracted using a RNeasy kit (QIAGEN, Hilden, Germany). RNA
was reverse-transcribed to cDNA using an Omniscript RT kit from QIAGEN (Hilden, Germany)
supplemented with a RNase inhibitor, according to the manufacturer’s instructions. The resulting
cDNA was analysed using TaqMan Universal Master Mix II (Life Technologies, Carlsbad, CA, USA).
Gene expression was determined using an Applied Biosystems 7300 real-time PCR system by the
comparative ∆∆CT method. All experiments were performed at least in triplicates, and data were
normalised to the housekeeping gene HPRT1 (in cells) or β-actin (in tissue). The primers used were
obtained from Thermo Fisher Scientific (Waltham, MA, USA) as follows: NQO1 (Hs00168547_m1),
AKR1B10 (Hs00252524_m1), NFE2L2 (Hs00975961_g1), HPRT1 (Hs02800695_m1) and β-actin
(Hs01060665_g1).
2.4. Focused Oxidative Stress Pathway Expression Analysis
The Human Oxidative Stress RT2 Profiler PCR Array (QIAGEN) profiled the expression of 84 genes
related to oxidative stress (ID 330231). The list of genes can be obtained from the QIAGEN webpage.
The analysis was performed in triplicates, including several internal controls and housekeeping genes,
and analysed using the QIAGEN in-house software (Software Version 2.0.4).
2.5. Cell Lysis Protocol and Western Blotting
Cells were washed and harvested in ice-cold phosphate-buffered saline (PBS), lysed in
Radioimmunoprecipitation assay buffer (RIPA) buffer and sonicated. Lysates were cleared by
centrifugation for 15 min at 4 ◦C. The supernatant was mixed with sodium dodecyl sulfate (SDS) sample
buffer and boiled for 5 min. Equal amounts of protein were separated by SDS-PAGE (polyacrylamide
gel electrophoresis), followed by semi-dry blotting to a polyvinylidene difluoride membrane (PVDF,
Thermo Fisher Scientific). After blocking of the membrane with 5% (w/v) Tris buffered saline with
Tween 20 (TBST) nonfat dry milk, primary antibodies were added. Appropriate secondary antibodies
coupled to horseradish peroxidase were detected by enhanced chemiluminescence using Clarity™
Western ECL (enhanced chemiluminescent) Blotting Substrate (Bio-Rad, Hercules, CA, USA).
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2.6. Drug Screening
Drug sensitivity and resistance testing (DSRT) [44] was performed on DLD1 NRF2 wild-type
(WT) and GOF cell lines in collaboration with The FIMM High-Throughput Biomedicine Unit at
the University of Helsinki (Helsinki, Finland). The compound library included 528 substances
consisting of conventional chemotherapeutics and a broad range of targeted oncology compounds.
The compounds were dissolved in dimethyl sulfoxide or water and dispensed on 384-well plates
(Corning, Corning, NY, USA). Each compound was plated at 5 concentrations covering a 10,000-fold
concentration range. The cells were incubated with the compounds, and after 72 h, cell toxicity and
viability were measured with CellToxGreen and CellTiter-Glo assays, respectively (Promega, Fitchburg,
WI, USA) using a Pherastar FS (BMG Labtech, Offenburg, Germany) plate reader. The data were
normalised to negative control wells (dimethyl sulfoxide only) and positive control wells containing
100-µM benzethonium chloride, which effectively kills all cells using a Breeze analysis pipeline [45].
To assess quantitative drug profiles for each sample, we calculated a drug sensitivity score (DSS) based
on the measured dose-response curves [46]. DSS is an integrative and robust drug response metric
based on the normalised area under the curve, which considers all four curve-fitting parameters in the
logistic model. The complete screening data is available in Supplementary Tables S1–S4.
2.7. Cell Viability Assays
Cells were seeded at a density of 2000 cells/well in 96-well plates, using three to five replicates
for each treatment condition. On the next day, cells were treated with either 0.1% DMSO or different
concentrations of AT9283 ranging from 10 nM to 10,000 nM. Treated cells were incubated for five days
at 37 ◦C.
Alamar Blue: Cell viability was determined by adding 20 µL of Alamar blue dye (Thermo Fischer
Scientific) to 200 µL of cell growth medium (DMEM). The plates were incubated with the dye for 3–6 h
at 37 ◦C, and the fluorescence (excitation at 570 nm and emission at 585 nm) was determined using a
standard plate reader.
Crystal Violet: Media was removed from plate wells and cells washed with PBS. Cells were fixed
using cold 4% paraformaldehyde (PFA) and kept on ice for twenty minutes. PFA was discarded,
and after washing with PBS, cells were incubated with 0.1% crystal violet at room temperature.
Twenty minutes later, crystal violet was removed, and the wells rinsed multiple times with dH2O,
until no blue dye could be seen in the rinse. Plates were then left to dry at room temperature before
adding 10% acetic acid. Absorbance was read at 590–600 nm.
2.8. In Silico Quantification of the NRF2 Activity in Colon and Rectal Tumours
To quantify in silico the NRF2 activity, we used the gene expression profiles of colon carcinoma
and rectal carcinoma tissues and of their normal counterparts obtained from the TCGA (The Cancer
Genome Atlas Program) project as harmonised datasets. Specifically, the first dataset was composed
of 478 primary tumours and 41 normal tissues, whereas the latter of 166 primary tumours and
10 normal tissues. Their gene expression data were downloaded as fragments per kilobase per
million mapped reads (FPKM) normalised expressions using the TCGAbiolinks package [47] (version
2.15.3) in R 3.5.0 (https://cran.r-project.org/). When present, multiple Ensembl IDs matching the same
gene symbol were collapsed to their median gene expression. The differential activity of NRF2 in
tumour and normal tissues was tested using the NRF2 target gene NQO1 and the combined use
of five well-known NRF2 validated target genes (“5-gene signature”). Additionally we also tested
(a) a gene set formed by 32 direct NRF2 targets (“NRF2 multi-tumour” [48]) identified in bladder
urothelial carcinoma, lung squamous cell carcinoma, head-neck squamous cell carcinoma and uterine
corpus endometrial carcinoma and (b) a signature formed by 20 NRF2 target genes identified in lung
cancer cells (“NRF2 lung” [49]). Signature scores for each gene set were obtained summarising the
standardized expression levels of the signature genes into a combined score with a zero mean [50].
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Differences between signature scores in tumour and normal samples were calculated using a Welch’s
t-test in R.
2.9. Immunohistochemistry
Immunohistochemistry was performed to assess the protein levels of NRF2 using the anti-NRF2
antibody from Santa Cruz (sc-365949) on a previously constructed tissue microarray (TMA) consisting
of 356 patients who underwent elective, potentially curative, resection for stage I-IV colorectal cancer
between 1997 and 2007 from Glasgow Royal Infirmary, Western Infirmary Glasgow and Stobhill
Hospital (Glasgow, UK). The selection criteria excluded patients who had neoadjuvant therapy,
died within 30 days of surgery or had metastasis. Local ethical approval was obtained from the
West of Scotland Research Ethics Committee (16/ws/0207; 14/03/2017), and tissue for this analysis was
obtained from the National Health Service Greater Glasgow and Clyde Tissue Biorepository (number
416; 10/10/2017) (Glasgow, UK).
Antibody specificity was confirmed using cell pellets prepared from WT and NRF2-GOF DLD1
cells. TMA sections (2.5 µm) were dewaxed by immersion in Histoclear, then rehydrated using
a series of alcohols. Heat-induced antigen retrieval was performed in a solution of Tris-EDTA
(ethylenediaminetetraacetic acid) pH9; after which, the sections were incubated in 3% hydrogen
peroxide. Nonspecific binding was blocked by incubation in 1.5% normal horse serum before being
incubate with NRF2 antibody (1:100) overnight at 4 ◦C. Staining was visualised with ImmPress
and 3,3′-diaminobenzidine (DAB) (both Vector Laboratories, Peterborough PE26XS, UK). Tissue was
counterstained using Harris haematoxylin before being dehydrated and mounted using DPX (dibutyl
phthalate in xylene).
The stained TMA sections were scanned using Hamamatsu NanoZoomer (Welwyn Garden City,
Hertfordshire, UK) at 20x magnification. Visualisation was carried out using Slidepath Digital Image
Hub version 4.0.1 (Slidepath, Leica Biosystems, Milton Keynes, UK). The weighted histoscore method
was employed to assess the protein expression by observer 1 (AR), with each protein being scored by
a second independent observer (JE) who scored 10% of all tumours to ensure consistency across the
study. Interclass correlation coefficients of greater than 0.8 were deemed acceptable and Bland Altman
plots carried out to ensure no scoring bias. All observers were blinded to the clinical and pathological
characteristics. Histoscores were calculated using the following formula: Total score = (% of unstainted
tumor cells × 0) + (% of weakly stained tumor cells × 1) + (% of moderately stained tumor cells × 2) +
(% of strongly stained tumor cells ×3), giving a range of 0 (minimum) to 300 (maximum). The results
were considered discordant if the histoscores differed by more than 50. Cytoplasmic and nuclear
expressions were calculated separately.
3. Results and Discussion
3.1. Analysis of the Status of the NRF2 Pathway in Colorectal Tumours
To investigate the status of NRF2 activity in colorectal tumours, we first interrogated large
databases of publicly available gene expression data from the TCGA project. Considering that the
NRF2 pathway is mainly activated by NRF2 stabilisation, NRF2 mRNA levels do not capture the status
of NRF2 activity. Therefore, and as there are no NRF2 transcriptional signatures validated in colorectal
tumours, we used well-known NRF2 target genes as surrogates for NRF2 activity: the prototypical
NRF2 target gene NQO1, which is often used as a surrogate for NRF2 activity, and, also, a combination
of five well-characterised and validated NRF2 target genes: NQO1, GPX2, TXNRD1, GCLC and GCLM
(all these genes were upregulated in our in vitro model of colorectal NRF2-GOF cells). We found that
both NQO1 and the combined NRF2 target genes were significantly enriched in colon tumours and
rectal tumours when compared with normal tissue (Figure 1A), suggesting that the NRF2 pathway is
activated in colorectal tumours. Additionally, we also tested two validated NRF2 signatures identified
in other tumour types (Supplementary Figure S1A): (a) a NRF2 signature identified in bladder urothelial
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carcinoma, lung squamous cell carcinoma, head-neck squamous cell carcinoma and uterine corpus
endometrial carcinoma [48] and (b) a NRF2 signature identified in lung cancer cells [49]. While the
NRF2 lung cancer signature was not enriched in either dataset, the NRF2 multi-tumour signature
was significantly upregulated in colon but not in rectal. Our data highlight the importance of the
identification and validation of a NRF2 signature specific for colorectal tumours, as signatures from
other tumour types might not be relevant.
To validate these in silico data, but restricted by the amount of material available, we compared
the NQO1 mRNA levels (as a surrogate for NRF2 activity) of nine chemo-naïve colorectal tumours and
matched normal tissue samples (Figure 1B). Eight out of the nine sample pairs displayed significantly
higher levels of NQO1 in the tumours compared to their corresponding matched normal tissue,
supporting our in silico data.
The next important question to answer was whether, similar to other cancer types,
NRF2 hyperactivation correlates with a poor prognosis in colorectal cancer. To directly address
this question, we analysed the protein levels of NRF2 on a tissue microarray (TMA) containing samples
from 365 colorectal cancer patients and their association with prognosis. We tested the specificity of
two different antibodies against human NRF2 in formalin-fixed paraffin-embedded (FFPE) cell pellets
of NRF2-GOF and NRF2-KO DLD1 cells (see cell validation for NRF2-GOF DLD1 cells in Figure 2
and for NRF2-KO DLD1 cells [41]). First, we compared the intensity of the IHC staining of NRF2-KO
versus NRF2-GOF cells using the NRF2 antibody 62,352 from Abcam (Cambridge, UK), which has
been previously used in human colorectal tissue [51,52]. However, there was no differential intensity
between the NRF2-KO and NRF2-GOF DLD1 cells, suggesting that the antibody was not specific
to NRF2 (Supplementary Figure S1B, upper panels). We then validated the specificity of a second
NRF2 antibody (sc-365949, Santa Cruz), which showed an intense nuclear signal in NRF2-GOF and
no staining of NRF2-KO cells (Supplementary Figure S1B, lower panels). Using the data obtained
from Santa Cruz antibody IHC staining (antibody validation shown in Supplementary Figure S1B,C),
we analysed whether nuclear NRF2 levels (and, thus, the transcriptionally active population) impact
the survival of colorectal cancer patients. Indeed, high protein levels of nuclear NRF2, correlated with
a decreased survival of colorectal cancer patients (p = 0.041) (Figure 1C), with a mean difference in
cancer-specific survival of 17 months between those patients with high NRF2 expressions versus those
with low NRF2 expressions. In addition, nuclear NRF2 levels significantly correlated with both the
proliferation index and defective DNA mismatch repair (MMR) status but not with other studied
clinical factors (Supplementary Figure S1C).
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Figure 1. Relevance of the nuclear factor erythroid 2 (NF-E2) p45-related factor 2 (NRF2) pathway in 
colorectal tumours in vivo. (A) Bioinformatic analysis of the expression of various NRF2 target genes 
in normal and tumour tissues. The activity of NRF2 in colon (upper row) and rectal (lower row) 
cancers (T) and normal (N) tissues of the TCGA project was assessed through the expression of the 
NRF2 target genes NQO1 (left) and through the combined score from the expression of NQO1, GPX2, 
TXNRD1, GCLC and GCLM (right). p: p-value of the Welch’s t-test. (B) NQO1 expression in matched 
normal and tumour colorectal tissue quantified using real-time PCR. Figures show the combined data 
(upper panel) or individual patients (lower panel). The data were normalised using β-actin as an 
internal control. Data represent means ± SD (n = 9). The differences between the tumour and the 
normal tissue for NQO1 were statistically significant (paired t-test analysis) (* p = 0.0401). (C) Kaplan-
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Figure 1. Relevance of the nuclear factor erythroid 2 (NF-E2) p45-related factor 2 (NRF2) pathway in
colorectal tumours in vivo. (A) Bioinformatic analysis of the expression of various NRF2 target genes in
normal and tumour tissues. The activity of NRF2 in colon (upper row) and rectal (lower row) cancers
(T) and normal (N) tissues of the TCGA project was assessed through the expression of the NRF2 target
genes NQO1 (left) and through the combined scor from the xpression of NQO1, GPX2, TXNRD1,
GCLC and GCLM (right). p: p-value of the Welch’s t-tes . (B) NQO1 expression in matched normal
and tumour colorectal tissue quantified using real-time PCR. Figures show the combined data (upper
panel) or individual patients (lower panel). The data were normalised using β-actin as an internal
control. Data represent means ± SD (n = 9). The differences between the tumour and the normal tissue
for NQO1 were statistically significant (paired t-test analysis) (* p = 0.0401). (C) Kaplan-Meier plots
showing differential cancer-specific survival for colorectal patients with high or low nuclear NRF2
levels (p = 0.041).
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Figure 2. Validation of a new colorectal cancer NRF2-GOF (gain-of-function) in vitro model. (A) 
Schematic representation of the NRF2 domains and the sequencing on the NRF2-GOF clones. (B) 
Isogenic NRF2-WT (wild-type) and NRF2-GOF DLD1 cell lines were treated with either DMSO (−) or 
with 5 μM of sulforaphane (SFN) (+) for 3 h, and the protein levels of NRF2 were compared. (C) The 
mRNA levels for NQO1 in the indicated cell lines treated with dimethyl sulfoxide (DMSO) or with 5 
μM of SFN for 16 h were quantified using real-time PCR. The data were normalised using β-actin as 
an internal control. Data represent means ± SD (n = 3) and are expressed relative to the WT DMSO 
cells. ** p ≤ 0.01. (D) Representation of the differential expression of oxidative stress-related genes in 
NRF2 WT versus NRF2-GOF. Highlighted either in red (upregulated) or in green (downregulated) 
are genes with more than 2-fold changes; only those with p-values < 0.05 were labelled (n = 3). 
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mRNA levels for NQO1 in the indicated cell lines treated with dimethyl sulfoxide (DMSO) or with
5 µM of SFN for 16 h were quantified using real-time PCR. The data were normalised using β-actin as
an internal control. Data represent means ± SD (n = 3) and are expressed relative to the WT DMSO
cells. ** p ≤ 0.01. (D) Representation of the differential expression of oxidative stress-related genes in
NRF2 WT versus NRF2-GOF. Highlighted either in red (upregulated) or in green (downregulated) are
genes with more than 2-fold changes; only those with p-values < 0.05 were labelled (n = 3).
Our data suggest that the NRF2 pathway is in fact activated in colorectal tumours, leading to
poorer patient prognosis.
3.2. Generation and Validation of a New Colorectal Cancer NRF2-GOF Cell-Based Model
To generate a colorectal cancer cell-based model that allows us to study the effects of the constitutive
activation of NRF2, we used the CRISPR/Cas9 system to generate isogenic stable cell lines. We designed
a single guide RNA (sgRNA) that targets the DLG motif of endogenous NRF2. This motif is one of
the two KEAP1-binding motifs within NRF2, and thus, its deletion disrupts the functional interaction
between NRF2 and KEAP1. Cas9-mediated DNA cleavage may result in out-of-frame DNA repair,
leading to NRF2-KO clones. However, most of the cell clones in which the DNA is repaired in-frame will
result in NRF2-GOF clones (as described in [41]) due to a mutation or deletion of the KEAP1-binding
sequence. These gain-of-function (GOF) deletions would functionally resemble some of the NRF2
mutations found in tumours [5,9,13].
To characterise the genetic alterations introduced by CRISPR into the DLD1 NRF2 GOF cell lines,
we sequenced a single cell-derived clone (Figure 2A). The sequencing showed that one of the NFE2L2
alleles was repaired in-frame, but the DLG motif was deleted, while the ETGE motif remained intact.
The second allele was null for NRF2 expression, as it was not repaired in-frame, which led to an early
stop codon. The resulting phenotype showed an activation of the NRF2 pathway, as demonstrated by
the increased protein levels of NRF2 (Figure 2B) and the correspondingly higher mRNA levels of the
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target gene NQO1 (Figure 2C); notably, these levels were much higher than those induced in response to
the pharmacological NRF2 activator sulforaphane (SFN). A pathway-focused gene expression analysis
for 86 antioxidant genes in NRF2-GOF versus NRF2-WT DLD1 cell lines (Figure 2D) further confirmed
the upregulation of well-established NRF2 target genes. Using the same gRNA, we generated an
isogenic NRF2-KO cell line and compared the mRNA levels of NQO1 and AKR1B10 of NRF2-WT,
NRF2-KO and NRF2-GOF cells (Supplementary Figure S2). The mRNA data suggests that the gRNA
used in this study is selective for the NFE2L2 gene locus; hence, the phenotypes observed are not due
to off-target effects.
Altogether, using the CRISPR/Cas9 system, we generated stable DLD1 cells harbouring the
constitutive activation of NRF2 by truncating one of the domains required for KEAP1 binding. This cell
line might be used as a tool to characterise the consequences of NRF2 activation in colorectal cancer.
3.3. Drug Screening
To identify drugs with selective cytotoxicity against colorectal cancer cells harbouring hyperactive
NRF2, we used our newly generated cell-based model. We tested the cytotoxicity potential of 528 drugs
(158 approved drugs, 285 investigational and 85 probes) in DLD1 cells with hyperactive NRF2
(NRF2-GOF) over DLD1 control cells (NRF2-WT). Two different analyses were performed to evaluate
the cytotoxic potential of these drugs, including a cell viability assay (namely CellTiter-Glo, CTG) and
cytotoxicity assay (CellTox-Green, CTX).
From this screen, the drug sensitivity score (DSS), which is an integrative and robust drug response
metric based on the normalised area under the curve (see Materials and Methods), was obtained.
Only compounds that had a difference in DSS between NRF2-GOF and NRF2-WT higher that five in
both analyses were considered positive hits. This analysis identified the Aurora kinase inhibitor AT9283
as the top candidate with selectivity against NRF2-GOF DLD1 cells (Figure 3A,B and Supplementary
Figure S3A,B). AT9283 is a synthetic small heterocyclic molecule that potently inhibits several kinases,
including Aurora A (3 nM), Aurora B (3 nM), JAK2 (1.2 nM), JAK3 (1.1 nM) and Abl (4.0 nM,
T315I) [53]. Importantly, Alisertib, a well-characterised Aurora A kinase inhibitor, also displayed
an increased selectivity against NRF2-GOF compared to the DLD1 control cells in both analyses
performed (Figure 3A). Other Aurora kinase inhibitors tested, including Tozasertib and Danusertib,
were significantly more potent against NRF2-GOF DLD1 cells in one of the analysis performed. The drug
screen also included other known Aurora kinase inhibitors (TAK 901, ENMD 2076, AZD A552-HQPA
and MK-8745) that, although they did not pass the set threshold, displayed a selective trend against
NRF2-GOF cells. Altogether, these analyses suggest that AT9283 selectively kill DLD1 cells harbouring
NRF2 hyperactivation through the inhibition of Aurora kinases.
AT9283 showed antimyeloma, antilymphoma, antileukaemia and anticolorectal cancer activity in
preclinical studies [54–59], and its safety and efficacy against myeloma, lymphoma and leukaemia
has been tested in various Phase I and II clinical trials [60–66]. Therefore, we focused our subsequent
studies on AT9283.
3.4. Validation of the Selectivity of AT9283 against Active NRF2
To validate the top hit from the screen, we tested the effect of AT9283 on the viability of NRF2-WT
and NRF2-GOF DLD1 cells after three days, using the Alamar blue assay as the readout (Figure 4A).
This assay confirmed the increased (by ~10-fold) sensitivity of the NRF2-GOF compared to NRF2-WT
cells: AT9283 had a half maximal inhibitory concentration (IC50) of 28 nM in NRF2-GOF cells versus
an IC50 of 320 nM in NRF2-WT cells. We further confirmed the effects of AT9283 on cell survival
using crystal violet staining, an ATP (adenosine triphosphate)-independent assay (Supplementary
Figure S4A), and, also, CellTiter-Glo, a luminescent ATP-dependent assay (Supplementary Figure S4B).
In both cases, the cells were incubated for five days with the drugs, and thus, the reduced sensitivity
was observed.
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Figure 3. Synthetic lethality drug screening. (A) Scatter plots showing the drug sensitivity score (DSS)
values of the Aurora kinase inhibitor compounds in the screening panel in DLD1 WT and GOF cells for
(upper panel) cell viability (CellTiter-Glo, CTG) and for (lower panel) cell toxicity (CellTox Green, CTX)
readouts. Labels show only Aurora kinase inhibitors. (B) Key drug response parameters of AT9283
in both WT and NRF2-GOF DLD1 cells are shown. TC50 (half-maximal toxic concentration), EC50
(half-maximal effective concentration), AUC (area under the curve) and DSS (drug sensitivity score).
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Figure 4. Validation of the selectivity of AT9283 against active NRF2. (A) NRF2-WT and GOF DLD1
cells were exposed to increasing concentrations of AT9283, as indicated. After three days, cell viability
was measured using Alamar blue. Data represent means ± SD (n = 4) and are expressed relative to the
DMSO control, which was set as 100%. (B) Upper panel: DLD1 cells were pretreated with the indicated
concentrations of NRF2 inducers or with DMSO, as indicated. After 24 h, fresh media with either
DMSO or 80-nM or 200-nM AT9283 was added, and NRF2 inducers were replenished. On the next day,
the NRF2 inducers were added again, and 24 h later, the cell viability was measured using Alamar
blue (n = 3). The viability of all control cells (without AT9283) were set as 100%. Lower panel: The cell
viability of control cells (without AT9283) treated with the different NRF2 inducers is shown. * p ≤ 0.05,
** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
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This analysis showed that AT9283 successfully “discriminates” between cell lines based on their
NRF2 activity, with cells with high levels of NRF2 activity (GOF) having an increased sensitivity
to AT9283.
To evaluate the potential therapeutic value of this selectivity against cells with high levels of
NRF2, and to further ensure that the observed effect is dependent on NRF2 activation and is not a
consequence of clonal artefacts, we tested whether the selective cytotoxicity could be recapitulated
by using pharmacological NRF2 activation. For this, we compared the effect on the viability of
NRF2-WT cells of three NRF2 activators that differ in potency and mechanism of action. Sulforaphane
(SFN) and TBE31 are two well-characterised electrophilic compounds that react with cysteine sensors
(primarily C151) of KEAP1, impairing its ability to target NRF2 for degradation [66]. By contrast,
HB229 is a nonelectrophilic small molecule that disrupts the KEAP1–NRF2 protein complex [43].
When NRF2-WT cells were treated with the NRF2 activators, we observed a significant sensitisation
towards the toxicity of AT9283 (Figure 4B, upper panel). Critically, the effect on cell viability was
completely dependent on AT9283 acting together with the NRF2 activator, as, at these concentrations,
neither AT9283 (Figure 4A,B) nor any of the NRF2 activators by themselves (Figure 4B, lower panel)
affected the viability of the cells. Of note, the sensitisation obtained with the pharmacological activation
of NRF2 was not as dramatic as the one observed with genetic activation. This is consistent with
the fact that the magnitude of the pharmacological activation of the pathway (measured by NQO1
levels) is significantly lower than that obtained with genetic modulation (Figure 2C and Supplementary
Figure S4C). Nevertheless, these results demonstrate that, similar to the genetic, the pharmacological
activation of NRF2 also sensitises DLD1 cells towards AT9283-mediated killing and further suggests
that AT9283 could be used in combination with an NRF2 activator to sensitise cells with normal
NRF2 levels.
4. Conclusions
In conclusion, we showed that, similar to other cancer types, NRF2 is hyperactivated in colorectal
tumours, which correlates with a poor prognosis. Furthermore, using a new model of a colorectal cancer
cell line with hyperactive NRF2, we identified a family of compounds (Aurora kinases inhibitors) and,
especially, the kinase inhibitor AT9283 for its selectivity against colorectal cancer cells with hyperactive
NRF2. Our study presents proof of concept data that the use of in vitro models of hyperactive NRF2
can identify drugs with specificity against cells with high NRF2 levels. This could have clinical
relevance for the treatment of tumours with hyperactive NRF2, as well as tumours with normal NRF2,
when combined with a pharmacological NRF2 activator. Further characterisation of this preferential
selectivity in other tumour types and in in vivo models is necessary to confirm the clinical potential of
this approach.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/10/1365/s1:
Figure S1: Bioinformatic analysis of the expression of two validated NRF2 transcriptional signatures in normal
and tumour tissue., Figure S2: The mRNA levels for NQO1 and AKR1B10 in the different cell lines were quantified
using real-time PCR, Figure S3: Scatter plots showing drug sensitivity score (DSS) values of DLD1 WT and GOF
cells with cell viability (CellTiter Glo, CTG, upper panel) and of cell toxicity (CellTox Green, CTX, lower panel)
readouts. and Figure S4: NRF2-WT and GOF DLD1 cells were exposed to increasing concentrations of AT9283
as indicated. Supplementary Table S1: Quality Control all plates, Table S2: Raw Data, Table S3: Cell viability
complete screening, Table S4: Cell cytotoxicity complete screening.
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